BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
nitric oxide metabolic process
,
Leukemia
,
Neuron
,
Nosology
,
Ciprofibrate
,
rs2476601
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
HO-%201
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for HO-%201
Explore Curated Studies Results
Literature
Most Relevant Literature
Cytotoxic effects of flavonoids against a human colon cancer derived cell line, COLO 201: a potentia…
Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from oxidative stress through in…
15-Deoxy-Δ(12,14)-prostaglandin J2 stabilizes hypoxia inducible factor-1α through induction of heme …
Transcriptomic analysis of key genes and pathways in human bronchial epithelial cells BEAS-2B expose…
The lower intestinal tract-specific induction of heme oxygenase-1 by glutamine protects against endo…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fib…
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FO…
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects
A Mobile Phone-based Intervention on Dementia Patients' Caregivers in Vietnam
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ